Cue Biopharma (CUE) EBITDA (2017 - 2025)
Cue Biopharma recorded quarterly EBITDA of $23.0 million in Q4 2025, up 409.51% quarter-over-quarter from -$7.4 million in Q3 2025, and up 342.72% year-over-year from $5.2 million in Q4 2024.
Cue Biopharma's EBITDA history runs 9 years deep, the most recent figure standing at $23.0 million for Q4 2025.
- In Q4 2025, EBITDA rose 342.72% year-over-year to $23.0 million; the TTM figure through Dec 2025 stood at -$5.1 million (up 87.37% YoY), while the FY2025 annual figure was -$5.5 million, up 86.52% from the prior year.
- EBITDA came in at $23.0 million for Q4 2025 at Cue Biopharma, up from -$7.4 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of $23.0 million in Q4 2025 to a low of -$14.6 million in Q4 2022.
- A 5-year average of -$9.7 million and a median of -$11.7 million in 2022 frame the typical range for EBITDA.
- Across the five-year window, EBITDA sank 74.09% in 2022 and surged 342.72% in 2025, its largest moves.
- Cue Biopharma's EBITDA stood at -$8.4 million in 2021, then sank by 74.09% to -$14.6 million in 2022, then climbed by 7.96% to -$13.4 million in 2023, then climbed by 29.31% to -$9.5 million in 2024, then jumped by 342.72% to $23.0 million in 2025.
- According to Business Quant data, EBITDA over the past three periods registered $23.0 million, -$7.4 million, and -$8.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -13.63 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.44 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 661.60 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 201.19 Mn |
| 10 | Cue Biopharma | 449.73 Mn | 422.04 Mn | - | 23.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 23.05 Mn |
| Sep 30, 2025 | -7.45 Mn |
| Jun 30, 2025 | -8.48 Mn |
| Mar 31, 2025 | -12.26 Mn |
| Dec 31, 2024 | -9.50 Mn |
| Sep 30, 2024 | -8.66 Mn |
| Jun 30, 2024 | -10.17 Mn |
| Mar 31, 2024 | -12.35 Mn |
| Dec 31, 2023 | -13.43 Mn |
| Sep 30, 2023 | -11.00 Mn |
| Jun 30, 2023 | -13.15 Mn |
| Mar 31, 2023 | -13.05 Mn |
| Dec 31, 2022 | -14.60 Mn |
| Sep 30, 2022 | -11.05 Mn |
| Jun 30, 2022 | -13.21 Mn |
| Mar 31, 2022 | -14.26 Mn |
| Dec 31, 2021 | -8.38 Mn |
| Sep 30, 2021 | -12.99 Mn |
| Jun 30, 2021 | -10.28 Mn |
| Mar 31, 2021 | -12.51 Mn |
| Dec 31, 2020 | -11.17 Mn |
| Sep 30, 2020 | -9.95 Mn |
| Jun 30, 2020 | -10.93 Mn |
| Mar 31, 2020 | -12.56 Mn |
| Dec 31, 2019 | -8.93 Mn |
| Sep 30, 2019 | -6.99 Mn |
| Jun 30, 2019 | -9.52 Mn |
| Mar 31, 2019 | -11.27 Mn |
| Dec 31, 2018 | -11.61 Mn |
| Sep 30, 2018 | -12.58 Mn |
| Jun 30, 2018 | -7.30 Mn |
| Mar 31, 2018 | -7.52 Mn |
| Dec 31, 2017 | -10.44 Mn |
| Sep 30, 2017 | -5.03 Mn |
| Jun 30, 2017 | -4.41 Mn |
| Mar 31, 2017 | -3.35 Mn |